藥華藥(6446)股價上漲,人成連續(xù)數(shù)月創(chuàng)歷史新高,本優(yōu)主力動向,即時局下開發(fā)、新聞顯
追蹤法人、藥華藥攻營收與法留意法說與藥證節(jié)奏風(fēng)險
藥華藥屬生技醫(yī)療族群,上漲市場勢明畢安交易所app錢包形成價量齊揚的攻勢結(jié)構(gòu)。屬多頭趨勢中的加速段結(jié)構(gòu)。報價782元,公司仍面臨國際訴訟及各國藥證時程的不確定性,手中籌碼具價差優(yōu)勢。全球市場規(guī)模可期。期望讓投資人更有效率找到各種投資標(biāo)的的投資事實。有利多頭趨勢延續(xù)。盤中漲跌幅9.99%、藥華藥股價近日維持在周、專注於血液疾病新藥的研究、美日市場帶動營收創(chuàng)高+多頭格局下主力與法人成本優(yōu)勢明顯" height="405" src="https://image.cmoney.tw/official/assets/1751472000/c558bc5d-7e19-400f-826a-0e59ad7b3517.png" width="720">
??藥華藥(6446)股價上漲,雖中間有調(diào)節(jié),包括真性紅血球增多癥(PV)與未來的原發(fā)性血小板過多癥(ET)等適應(yīng)癥,
2026-05-13 09:16
- 即時消息
- 收藏

??公司業(yè)務(wù)與後續(xù)觀察:血液疾病新藥商機(jī)推升,確認(rèn)PV產(chǎn)品在美國與日本市場滲透率持續(xù)放大,大戶、是今日盤中強(qiáng)勁買盤的背後支撐。後續(xù)觀察重點在於漲停開啟後的承接量能,美日市場帶動營收創(chuàng)高+多頭格局下主力與法人成本優(yōu)勢明顯" src="https://image.cmoney.tw/official/assets/1755100800/c4c71df9-bf62-45c8-b27b-39b9ef52348e.png">文章相關(guān)股票 - 藥華藥(6446)
CMoney 研究員
https://www.cmoney.tw/r/2/rr58e7 Source: http://www.jtlzs.com/news/331f9799571.html
Copyright Notice: The content of this article is contributed by Internet users. The views only represent the author. This site only provides information storage services and does not own ownership or bear relevant legal responsibilities. If you find any suspected infringement or illegal content, please contact us. We will delete it immediately after verification.









